MBX Biosciences Inc. (NASDAQ: MBX) announced that its once-weekly canvuparatide treatment achieved the primary endpoint in a Phase 2 trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE